One of the main advantages of SGLT-2 inhibitor monotherapy is the ability of a single drug to provide better glycemic control and reduce insulin resistance whilst also improving NAFLD features and reducing body weight. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.